AR095367A1 - Conjugado de péptido inmunogénico y método para inducir una respuesta del anticuerpo terapéutico anti-influenza - Google Patents
Conjugado de péptido inmunogénico y método para inducir una respuesta del anticuerpo terapéutico anti-influenzaInfo
- Publication number
- AR095367A1 AR095367A1 ARP140100906A ARP140100906A AR095367A1 AR 095367 A1 AR095367 A1 AR 095367A1 AR P140100906 A ARP140100906 A AR P140100906A AR P140100906 A ARP140100906 A AR P140100906A AR 095367 A1 AR095367 A1 AR 095367A1
- Authority
- AR
- Argentina
- Prior art keywords
- protein
- influenza
- hemagglutinin
- immunogenic peptide
- conjugate
- Prior art date
Links
- 206010022000 influenza Diseases 0.000 title abstract 9
- 230000002163 immunogen Effects 0.000 title abstract 6
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 230000001225 therapeutic effect Effects 0.000 title abstract 3
- 230000005875 antibody response Effects 0.000 title abstract 2
- 101710154606 Hemagglutinin Proteins 0.000 abstract 9
- 101710093908 Outer capsid protein VP4 Proteins 0.000 abstract 9
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 abstract 9
- 101710176177 Protein A56 Proteins 0.000 abstract 9
- 239000000185 hemagglutinin Substances 0.000 abstract 8
- 102000004169 proteins and genes Human genes 0.000 abstract 6
- 108090000623 proteins and genes Proteins 0.000 abstract 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 abstract 5
- 229940098773 bovine serum albumin Drugs 0.000 abstract 5
- 239000000863 peptide conjugate Substances 0.000 abstract 5
- 102000014914 Carrier Proteins Human genes 0.000 abstract 3
- 108010078791 Carrier Proteins Proteins 0.000 abstract 3
- 230000004927 fusion Effects 0.000 abstract 3
- 108060003552 hemocyanin Proteins 0.000 abstract 3
- 102220637010 Actin-like protein 7A_S10T_mutation Human genes 0.000 abstract 2
- 241000701822 Bovine papillomavirus Species 0.000 abstract 2
- 241000701806 Human papillomavirus Species 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 239000000562 conjugate Substances 0.000 abstract 2
- 230000000977 initiatory effect Effects 0.000 abstract 2
- 241000712461 unidentified influenza virus Species 0.000 abstract 2
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 abstract 1
- 108090000565 Capsid Proteins Proteins 0.000 abstract 1
- 102100023321 Ceruloplasmin Human genes 0.000 abstract 1
- 241000975300 Concholepas concholepas Species 0.000 abstract 1
- 102000016607 Diphtheria Toxin Human genes 0.000 abstract 1
- 108010053187 Diphtheria Toxin Proteins 0.000 abstract 1
- 101000597577 Gluconacetobacter diazotrophicus (strain ATCC 49037 / DSM 5601 / CCUG 37298 / CIP 103539 / LMG 7603 / PAl5) Outer membrane protein Proteins 0.000 abstract 1
- 101710146275 Hemagglutinin 2 Proteins 0.000 abstract 1
- 241000700721 Hepatitis B virus Species 0.000 abstract 1
- 101710116435 Outer membrane protein Proteins 0.000 abstract 1
- 108010058846 Ovalbumin Proteins 0.000 abstract 1
- 241000702670 Rotavirus Species 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 210000000170 cell membrane Anatomy 0.000 abstract 1
- 125000005647 linker group Chemical group 0.000 abstract 1
- 229940092253 ovalbumin Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102200058937 rs45581936 Human genes 0.000 abstract 1
- 102220234440 rs572685299 Human genes 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 229960000814 tetanus toxoid Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Los conjugados portadores de péptidos inmunogénicos derivados de hemaglutinina de influenza descritos en este documento inducen una respuesta terapéutica de anticuerpos específica contra el virus de la influenza. Los conjugados de péptidos inmunogénicos comprenden un segmento del dominio de la región de iniciación de fusión (FIR) de un conjugado de proteína de hemaglutinina de la gripe conjugado a una proteína portadora, tal como hemocianina de lapa californiana (KLH), albúmina de suero bovino (BSA), una proteína de hemaglutinina de la gripe (HA) (es decir, HA de longitud completa), y similares. Los conjugados de péptidos inmunogénicos descritos aquí se pueden utilizar para prevenir o tratar la infección de la gripe y para preparar anticuerpos terapéuticos específicos de la influenza que interfieren con la fusión de la membrana celular huésped del virus de la influenza. Los conjugados de péptidos se pueden formular en composiciones farmacéuticas útiles para el tratamiento de amplio espectro o la prevención de infecciones de gripe. Reivindicación 1: Un conjugado de péptido inmunogénico que comprende un péptido (FIR) de región de fusión de iniciación hemaglutinina (HA) o una variante del mismo, conjugado con una proteína portadora por un grupo de enlace, en donde el péptido FIR HA consiste en no más de 50 residuos de aminoácidos y comprende un segmento de una proteína hemaglutinina 2 de influenza que incluye la secuencia de aminoácidos SEQ ID Nº 1 o una variante de SEQ ID Nº 1 que comparte al menos 50% de identidad de la secuencia con la misma y que difieren de la SEQ ID Nº 1 por una o más sustituciones de aminoácidos seleccionadas del grupo que consiste en V1i, V1L, V1A, V1G, V1T, V1S, V1M, E2D, E2E, E2R, D3E, T4G, T4S, T4Q, T4A, K5F, K5M, K5I, K5V, K5L, K5A, I6L, I6V, I6a, I6T, I6S, I6Q, I6N, D7E, L8I, L8V, L8A, W9Y, S10T, S10G, S10A, S10M y E14K. Reivindicación 5: El conjugado de péptido inmunogénico de una cualquiera de las reivindicaciones 1 a 4, donde la proteína portadora se selecciona del grupo que consiste en el complejo de proteína de membrana externa de Neiserría meningitidis (OMPC), proteína toxoide del tétanos, derivado CRM197 de la toxina de difteria, albúmina de suero bovino (BSA), BSA cationizado, hemocianina Concholepas concholepas (CCH), la proteína de antígeno de superficie del virus de la hepatitis B (VHB) (HBsAg), proteínas antigénica de núcleo VHB, hemocianina de lapa californiana (KLH), la proteína del cápside del rotavirus, proteína L1 del virus del papiloma bovino (BPV), proteína L1 del virus del papiloma humano (VPH), ovoalbúmina, y proteína hemaglutinina de longitud completa de la gripe.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/828,988 US9649375B2 (en) | 2013-03-14 | 2013-03-14 | Immunogenic peptide conjugate and method for inducing an anti-influenza therapeutic antibody response therewith |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR095367A1 true AR095367A1 (es) | 2015-10-14 |
Family
ID=51527967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140100906A AR095367A1 (es) | 2013-03-14 | 2014-03-12 | Conjugado de péptido inmunogénico y método para inducir una respuesta del anticuerpo terapéutico anti-influenza |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US9649375B2 (es) |
| EP (1) | EP2970386A4 (es) |
| JP (1) | JP2016519061A (es) |
| CN (1) | CN105377876A (es) |
| AR (1) | AR095367A1 (es) |
| AU (2) | AU2014244071B2 (es) |
| CA (1) | CA2906519A1 (es) |
| EA (1) | EA030004B1 (es) |
| HK (1) | HK1222184A1 (es) |
| MX (1) | MX2015012399A (es) |
| TW (2) | TWI654205B (es) |
| WO (1) | WO2014160171A2 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190343951A1 (en) * | 2017-01-13 | 2019-11-14 | National Research Council Of Canada | Method of optimizing peptide immuno-epitope by glycosylation, optimized peptide thereof and its use for conjugate vaccines |
| WO2018237010A2 (en) | 2017-06-20 | 2018-12-27 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | VACCINE COMPOSITIONS AGAINST STREPTOCOCCUS AND THEIR METHODS OF USE |
| CN114516907B (zh) * | 2020-11-20 | 2024-03-29 | 中国科学技术大学 | 一种植物抗逆性相关基因atagl70及其编码蛋白与应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2047073A1 (en) | 1990-07-19 | 1992-01-20 | William J. Leanza | Coconjugate vaccines comprising immunogenic protein, hiv related peptides, and anionic moieties |
| US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| US5824307A (en) | 1991-12-23 | 1998-10-20 | Medimmune, Inc. | Human-murine chimeric antibodies against respiratory syncytial virus |
| US5589174A (en) * | 1992-09-17 | 1996-12-31 | Takara Shuzo Co., Ltd. | Anti-human influenza virus antibody |
| US6479055B1 (en) * | 1993-06-07 | 2002-11-12 | Trimeris, Inc. | Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission |
| DK1034298T3 (da) | 1997-12-05 | 2012-01-30 | Scripps Research Inst | Humanisering af murint antistof |
| DE60041335D1 (de) * | 1999-08-19 | 2009-02-26 | Dynavax Tech Corp | Methode zur modulierung eines immunantwortes mit immunstimulierenden sequencen und zusammensetzungen dafür |
| US7189800B2 (en) * | 2001-03-27 | 2007-03-13 | Samuel Bogoch | Replikin peptides in rapid replication of glioma cells and in influenza epidemics |
| AU2003243651B2 (en) | 2002-06-17 | 2008-10-16 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Specificity grafting of a murine antibody onto a human framework |
| EP2261380B1 (en) * | 2003-11-04 | 2013-07-17 | The Administrators of the Tulane Educational Fund | Method of preventing virus:cell fusion by inhibiting the function of the fusion initiation region in rna viruses having class I membrane fusogenic envelope proteins |
| HUE026136T2 (en) * | 2005-10-18 | 2016-05-30 | Novavax Inc | Functional influenza virus-like particles (VLP-K) |
| US20090169576A1 (en) | 2005-10-26 | 2009-07-02 | Roberto Crea | Influenza combinatorial antigen vaccine |
| US8222204B2 (en) * | 2006-05-03 | 2012-07-17 | The Administrators of the Tulane Educational Fund and Autoimmune Technologies, LLC | Influenza inhibiting compositions and methods |
| MX2008015309A (es) | 2006-05-31 | 2009-03-02 | Astellas Pharma Inc | Anticuerpo humanizado de osteopontina anti-humana. |
| MX363240B (es) * | 2007-06-25 | 2019-03-15 | The Administrators Of The Tulane Educational Fund | Composiciones que inhiben la influenza y métodos. |
| US8669046B2 (en) * | 2008-03-12 | 2014-03-11 | Xuguang (Sean) Li | Reagents and methods for detecting influenza virus proteins |
| JP2012521786A (ja) | 2009-03-30 | 2012-09-20 | モウント シナイ スクール オフ メディシネ | インフルエンザウイルスワクチン及びその使用 |
| EP2424879A4 (en) | 2009-04-29 | 2013-06-05 | Ca Minister Health & Welfare | INFLUENZA VACCINE |
| WO2010124393A1 (en) | 2009-04-30 | 2010-11-04 | National Research Council Of Canada | Anticancer agent comprising a yatapoxvirus mutant and uses thereof |
| WO2010130636A1 (en) | 2009-05-11 | 2010-11-18 | Crucell Holland B.V. | Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof |
| CN102939101A (zh) * | 2010-01-26 | 2013-02-20 | 科罗拉多大学董事会，法人 | 用于通用疫苗的流感病毒组合物和方法 |
| MX346206B (es) | 2011-07-14 | 2017-03-09 | Crucell Holland Bv | Moleculas de enlace humanas capaces de neutralizar los virus de la influenza a del grupo filogenetico 1 y grupo filogenetico 2 y virus de la influenza b. |
-
2013
- 2013-03-14 US US13/828,988 patent/US9649375B2/en active Active
-
2014
- 2014-03-12 AR ARP140100906A patent/AR095367A1/es unknown
- 2014-03-13 WO PCT/US2014/025968 patent/WO2014160171A2/en active Application Filing
- 2014-03-13 TW TW103109171A patent/TWI654205B/zh not_active IP Right Cessation
- 2014-03-13 EA EA201591747A patent/EA030004B1/ru not_active IP Right Cessation
- 2014-03-13 AU AU2014244071A patent/AU2014244071B2/en not_active Ceased
- 2014-03-13 EP EP14776544.0A patent/EP2970386A4/en not_active Withdrawn
- 2014-03-13 MX MX2015012399A patent/MX2015012399A/es unknown
- 2014-03-13 CN CN201480028403.5A patent/CN105377876A/zh active Pending
- 2014-03-13 JP JP2016502011A patent/JP2016519061A/ja active Pending
- 2014-03-13 TW TW107137751A patent/TW201925238A/zh unknown
- 2014-03-13 CA CA2906519A patent/CA2906519A1/en not_active Abandoned
-
2016
- 2016-08-31 HK HK16110325.7A patent/HK1222184A1/zh unknown
-
2017
- 2017-05-10 US US15/591,386 patent/US10137194B2/en active Active - Reinstated
-
2018
- 2018-10-04 AU AU2018241125A patent/AU2018241125A1/en not_active Abandoned
- 2018-10-31 US US16/176,743 patent/US10537634B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014244071A1 (en) | 2015-10-29 |
| US10537634B2 (en) | 2020-01-21 |
| TW201514208A (zh) | 2015-04-16 |
| HK1222184A1 (zh) | 2017-06-23 |
| EP2970386A2 (en) | 2016-01-20 |
| TWI654205B (zh) | 2019-03-21 |
| US20190054168A1 (en) | 2019-02-21 |
| WO2014160171A3 (en) | 2015-04-23 |
| TW201925238A (zh) | 2019-07-01 |
| CA2906519A1 (en) | 2014-10-02 |
| US20140271650A1 (en) | 2014-09-18 |
| US10137194B2 (en) | 2018-11-27 |
| CN105377876A (zh) | 2016-03-02 |
| AU2018241125A1 (en) | 2018-10-25 |
| WO2014160171A2 (en) | 2014-10-02 |
| JP2016519061A (ja) | 2016-06-30 |
| EP2970386A4 (en) | 2016-10-26 |
| AU2014244071B2 (en) | 2018-07-05 |
| US9649375B2 (en) | 2017-05-16 |
| US20170258902A1 (en) | 2017-09-14 |
| EA201591747A1 (ru) | 2016-02-29 |
| EA030004B1 (ru) | 2018-06-29 |
| MX2015012399A (es) | 2016-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2563646T3 (es) | Composiciones y métodos relacionados con variantes de la proteína A (SpA) | |
| Denis et al. | Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform | |
| UY37811A (es) | Una composición inmunogénica que tiene estabilidad mejorada, inmunogeneicidad potenciada y reactogenicidad reducida y proceso para la preparación de la misma | |
| CL2008002559A1 (es) | Construccion que comprende un vector de fluorocarbono y un antigeno del virus de la influenza; composicion farmaceutica que lo comprende; y su uso para aumentar la respuesta inmunologica | |
| US20090081253A1 (en) | Composition | |
| AR095367A1 (es) | Conjugado de péptido inmunogénico y método para inducir una respuesta del anticuerpo terapéutico anti-influenza | |
| CL2013003248A1 (es) | Composición inmunogenica que comprende una glucoproteina g de los virus hendra y nipah y un complejo inmunoestimulante; método para producir una respuesta de anticuerpo neutralizante contra un virus hendra y/o nipah en un sujeto. | |
| PE20161560A1 (es) | Vacuna de pcsk9 | |
| WO2008014521A3 (en) | Improved vaccines and methods for using the same | |
| RU2007145052A (ru) | Композиции пептидного конъюгата и способы для профилактики и лечения болезни альцгеймера | |
| JP2009511084A5 (es) | ||
| NO20050396L (no) | Adjuvant viral partikkel | |
| RU2015138530A (ru) | Комбинированная вакцина против респираторно-синцитиального вируса и вируса гриппа | |
| AR092896A1 (es) | Composiciones inmunogenicas | |
| MX2018015506A (es) | Vacuna contra virus de bronquitis infecciosa. | |
| WO2011048386A1 (en) | Influenza vaccine | |
| RU2007130148A (ru) | Пептиды для введения вакцин через слизистую оболочку | |
| Heinimäki et al. | Antigenicity and immunogenicity of HA2 and M2e influenza virus antigens conjugated to norovirus-like, VP1 capsid-based particles by the SpyTag/SpyCatcher technology | |
| WO2016087863A1 (en) | Vaccines based on hepatitis b core antigens | |
| JP2018501258A5 (es) | ||
| AR095425A1 (es) | Vacuna, uso y procedimiento para prevenir una infección por picornavirus | |
| PE20200004A1 (es) | Composicion de vacuna multivalente novedosa | |
| JP2019043937A5 (es) | ||
| JP2016519061A5 (es) | ||
| Wang et al. | DNA prime and virus-like particle boost from a single H5N1 strain elicits broadly neutralizing antibody responses against head region of H5 hemagglutinin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |